




INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification <sup>6</sup> : G01N 33/49, 33/86, G06F 19/00		A1	(11) International Publication Number: WO 99/34208
			(43) International Publication Date: 8 July 1999 (08.07.99)
(21) International Application Number: PCT/US98/27865 (22) International Filing Date: 30 December 1998 (30.12.98) (30) Priority Data: 09/001,647 31 December 1997 (31.12.97) US (63) Related by Continuation (CON) or Continuation-in-Part (CIP) to Earlier Application US 09/001,647 (CIP) Filed on 31 December 1997 (31.12.97) (71) Applicant (for all designated States except US): AKZO NOBEL N.V. [NL/NL]; Velperweg 76, P.O. Box 186, NL-6800 LS Arnhem (NL). (72) Inventors; and (75) Inventors/Applicants (for US only): BRAUN, Paul [US/US]; 612 Kingsbury Drive, Durham, NC 27712 (US). GIVENS, Thomas, B. [US/US]; 3522 Red Mountain Road, Rouge- mont, NC 27572 (US). FISCHER, Timothy, J. [US/US]; 4825 Winterwood Drive, Raleigh, NC 27613 (US). (74) Agents: BLACKSTONE, William et al.; Akzo Nobel, Patent Dept., 1300 Piccard Drive #206, Rockville, MD 20850 (US).		(81) Designated States: AU, CA, JP, KR, US, European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE). Published With international search report. Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.	

(54) Title: A METHOD FOR PREDICTING AN ABNORMAL LEVEL OF CLOTTING PROTEINS

**(57) Abstract**

A method is disclosed for predicting the presence of an abnormal level of one or more proteins in the clotting cascade from at least one time-dependent measurement profile. At least one time-dependent measurement on an unknown sample (103) is performed and a respective property of the sample is measured over time so as to derive a time-dependent measurement profile (101). A set of a plurality of predictor variables (110) are defined which sufficiently define the data of the time-dependent measurement profile (101). A model (113) is then derived that represents the relationship between the abnormality and the set of predictor variables (110). Subsequently, the model (113) is utilized to predict which protein or proteins in the clotting cascade are at an abnormal level, with the prediction (120) being a better prediction than clot time alone.



**BEST AVAILABLE COPY**

**FOR THE PURPOSES OF INFORMATION ONLY**

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece	ML	Mali	TR	Turkey
BG	Bulgaria	HU	Hungary	MN	Mongolia	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MR	Mauritania	UA	Ukraine
BR	Brazil	IL	Israel	MW	Malawi	UG	Uganda
BY	Belarus	IS	Iceland	MX	Mexico	US	United States of America
CA	Canada	IT	Italy	NE	Niger	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NL	Netherlands	VN	Viet Nam
CG	Congo	KE	Kenya	NO	Norway	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NZ	New Zealand	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	PL	Poland		
CM	Cameroon	KR	Republic of Korea	PT	Portugal		
CN	China	KZ	Kazakhstan	RO	Romania		
CU	Cuba	LC	Saint Lucia	RU	Russian Federation		
CZ	Czech Republic	LI	Liechtenstein	SD	Sudan		
DE	Germany	LK	Sri Lanka	SE	Sweden		
DK	Denmark	LR	Liberia	SG	Singapore		
EE	Estonia						

## A METHOD FOR PREDICTING AN ABNORMAL LEVEL OF CLOTTING PROTEINS

BACKGROUND OF THE INVENTION

- 5        This application is a continuation-in-part of  
U.S. patent application 08/859,773 to Givens et al.  
filed May 21, 1997, which is a continuation of U.S.  
patent application 08/477,839 to Givens et al. filed  
June 7, 1995. This application also relates to U.S.  
10    patent 5,646,046 to Fischer et al, the subject matter  
of which is incorporated herein by reference. This  
application is further related to the following  
publications, the subject matter of each  
also being incorporated herein by reference:
- 15        1.    B. Pohl, C. Beringer, M. Bomhard, F. Keller,  
The quick machine - a mathematical model for the  
extrinsic activation of coagulation, *Haemostasis*, 24,  
325-337 (1994).
- 20        2.    J. Brandt, D. Triplett, W. Rock, E. Bovill,  
C. Arkin, Effect of lupus anticoagulants on the  
activated partial thromboplastin time, *Arch Pathol Lab*  
*Med*, 115, 109-14 (1991).
- 25        3.    I. Talstad, Which coagulation factors  
interfere with the one-stage prothrombin time?,  
*Haemostasis*, 23, 19-25 (1993).
- 30        4.    P. Baumann, T. Jurgensen, C. Heuck,  
Computerized analysis of the in vitro activation of  
the plasmatic clotting system, *Haemostasis*, 19, 309-  
321 (1989).
- 35        5.    C. Heuck, P. Baumann, Kinetic analysis of  
the clotting system in the presence of heparin and  
depolymerized heparin, *Haemostasis*, 21, 10-18 (1991).
6.    M. Astion and P. Wilding, The application of  
backpropagation neural networks to problems in

-2-

pathology and laboratory medicine, *Arch Pathol Lab Med*, 116, 995-1001 (1992).

7. M. Astion, M. Wener, R. Thomas, G. Hunder,  
5 and D. Bloch, Overtraining in neural networks that  
interpret clinical data, *Clinical Chemistry*, 39,  
1998-2004 (1993).

8. J. Furlong, M. Dupuy, and J. Heinsimer,  
10 Neural network analysis of serial cardiac enzyme data,  
*A.J.C.P.*, 96, 134-141 (1991).

9. W. Dassen, R. Mulleneers, J. Smeets, K. den  
Dulk, F. Cruz, P. Brugada, and H. Wellens, Self-  
15 learning neural networks in electrocardiography, *J.*  
*Electrocardiol*, 23, 200-202 (1990).

10. E. Baum and D. Haussler, What size net gives  
valid generalization? *Advances in Neural Information*  
20 *Processing Systems*, Morgan Kaufman Publishers, San  
Mateo, CA, 81-90 (1989).

11. A. Blum, *Neural Networks in C++*, John Wiley  
& Sons, New York, (1992).  
25

12. S. Haykin, *Neural Networks A Comprehensive*  
*Foundation*, Macmillan College Publishing Company, New  
York, (1994).

13. J. Swets, Measuring the accuracy of  
30 diagnostic systems, *Science*, 240, 1285-1293 (1988).

14. M. Zweig and G. Campbell, Receiver-operating  
characteristic (ROC) plots: a fundamental evaluation  
35 tool in clinical medicine, *Clinical Chemistry*, 39,  
561-577 (1993).

-3-

15. D. Bluestein, L. Archer, The sensitivity, specificity and predictive value of diagnostic information: a guide for clinicians, *Nurse Practitioner*, 16, 39-45 (1991).

5

16. C. Schweiger, G. Soeregi, S. Spitzauer, G. Maenner, and A. Pohl, Evaluation of laboratory data by conventional statistics and by three types of neural networks, *Clinical Chemistry*, 39, 1966-1971 (1993).

10

Blood clots are the end product of a complex chain reaction where proteins form an enzyme cascade acting as a biologic amplification system. This system enables relatively few molecules of initiator products to induce sequential activation of a series of inactive proteins, known as factors, culminating in the production of the fibrin clot. Mathematical models of the kinetics of the cascade's pathways have been previously proposed.

15

20

In [1], a dynamic model of the extrinsic coagulation cascade was described where data were collected for 20 samples using quick percent, activated partial thromboplastin time (APTT), thrombin time (TT), fibrinogen, factor(F) II, FV, FVII, FX, anti-thrombin III (ATIII), and factor degradation product (FDP) assays. These data were used as input to the model and the predictive output compared to actual recovered prothrombin time (PT) screening assay results. The model accurately predicted the PT result in only 11 of 20 cases. These coagulation cascade models demonstrate: (1) the complexity of the clot formation process, and (2) the difficulty in associating PT clot times alone with specific conditions.

25

30

35

-4-

Thrombosis and hemostasis testing is the in vitro study of the ability of blood to form clots and to break clots in vivo. Coagulation (hemostasis) assays began as manual methods where clot formation was  
5 observed in a test tube either by tilting the tube or removing fibrin strands by a wire loop. The goal was to determine if a patients blood sample would clot after certain materials were added. It was later determined that the amount of time from initiation of  
10 the reaction to the point of clot formation in vitro is related to congenital disorders, acquired disorders, and therapeutic monitoring. In order to remove the inherent variability associated with the subjective endpoint determinations of manual  
15 techniques, instrumentation has been developed to measure clot time, based on (1) electromechanical properties, (2) clot elasticity, (3) light scattering, (4) fibrin adhesion, and (5) impedance. For light scattering methods, data is gathered that represents  
20 the transmission of light through the specimen as a function of time (an optical time-dependent measurement profile).

Two assays, the PT and APTT, are widely used to screen for abnormalities in the coagulation system,  
25 although several other screening assays can be used, e.g. protein C, fibrinogen, protein S and/or thrombin time. If screening assays show an abnormal result, one or several additional tests are needed to isolate the exact source of the abnormality. The PT and APTT  
30 assays rely primarily upon measurement of time required for clot time, although some variations of the PT also use the amplitude of the change in optical signal in estimating fibrinogen concentration.

Blood coagulation is affected by administration  
35 of drugs, in addition to the vast array of internal factors and proteins that normally influence clot

-5-

formation. For example, heparin is a widely-used therapeutic drug that is used to prevent thrombosis following surgery or under other conditions, or is used to combat existing thrombosis. The  
5 administration of heparin is typically monitored using the APTT assay, which gives a prolonged clot time in the presence of heparin. Clot times for PT assays are affected to a much smaller degree. Since a number of other plasma abnormalities may also cause prolonged  
10 APTT results, the ability to discriminate between these effectors from screening assay results may be clinically significant.

Using a sigmoidal curve fit to a profile, Baumann, et al [4] showed that a ratio of two  
15 coefficients was unique for a select group of blood factor deficiencies when fibrinogen was artificially maintained by addition of exogenous fibrinogen to a fixed concentration, and that same ratio also correlates heparin to FII deficiency and FXa  
20 deficiencies. However, the requirement for artificially fixed fibrinogen makes this approach inappropriate for analysis of clinical specimens. The present invention makes it possible to predict a congenital or acquired imbalance or therapeutic  
25 condition for clinical samples from a time-dependent measurement profile without artificial manipulation of samples.

The present invention was conceived of and developed for predicting the presence of congenital or  
30 acquired imbalances or therapeutic conditions of an unknown sample based on one or more time-dependent measurement profiles, such as optical time-dependent measurement profiles, where a set of predictor variables are provided which define characteristics of  
35 profile, and where in turn a model is derived that represents the relationship between a congenital or

-6-

acquired imbalance or therapeutic condition and the set of predictor variables (so as to, in turn, utilize this model to predict the existence of the congenital or acquired imbalance or therapeutic condition in the unknown sample).

#### SUMMARY OF THE INVENTION

The present invention is directed to a method and apparatus for predicting the presence of at least one congenital or acquired imbalance or therapeutic condition from at least one time-dependent measurement profile. The method and apparatus include a) performing at least one assay on an unknown sample and measuring a respective property over time so as to derive a time-dependent measurement profile, b) defining a set of predictor variables which sufficiently define the data of the time-dependent profile, c) deriving a model that represents the relationship between a diagnostic output and the set of predictor variables, and d) utilizing the model to predict the existence of a congenital or acquired imbalance or therapeutic condition in the unknown sample relative to the diagnostic output. In one embodiment, training data is provided by performing a plurality of assays on known samples, the model is a multilayer perceptron, the relationship between the diagnostic output and the set of predictor variables is determined by at least one algorithm, and the at least one algorithm is a back propagation learning algorithm. In a second embodiment of the present invention, the relationship between the diagnostic output and the set of predictor variables is derived by a set of statistical equations. Also in the present invention, a plurality of time-dependent measurement profiles are derived, which time-dependent

-7-

measurement profiles can be optical time-dependent measurement profiles such as ones provided by a automated analyzer for thrombosis and hemostasis, where a plurality of optical measurements are taken  
5 over time, and where the plurality of optical measurements are normalized. The optical profiles can include one or more of a PT profile, a fibrinogen profile, an APTT profile, a TT profile, a protein C profile, a protein S profile and a plurality of other  
10 assays associated with congenital or acquired imbalances or therapeutic conditions.

#### BRIEF DESCRIPTION OF THE DRAWINGS

Figure 1 is a general neuron diagram relating to  
15 the embodiment of the present invention utilizing a neural network;

Figure 2 is a diagram of a multilayer perceptron for predicting congenital or acquired imbalances or therapeutic conditions, relating to the neural network  
20 embodiment of the present invention;

Figure 3 is an optical profile with first and second derivatives of a normal clotting sample;

Figure 4 is an illustration of two learning curves;

25 Figure 5 is an illustration of an unstable learning curve;

Figure 6 is a graph showing a comparison of training and cross-validation learning curves;

Figure 7 is a graph showing a comparison of  
30 training error for training tolerances of 0.0 and 0.1;

-8-

Figure 8 is a ROC illustrating the effect of decision boundary on classification;

Figure 9 is a Table comparing hidden layer size with prediction error;

5        Figure 10 is a receiver operator characteristic plot related to predicting an abnormality in relation to Factor VIII;

Figure 11 is a graph demonstrating the ability to predict actual Factor VIII activity;

10       Figure 12 is a receiver operator characteristic plot related to predicting an abnormality in relation to Factor X;

Figure 13 is a chart listing examples of predictor variables for use in the present invention;

15       Figures 14 - 21 show ROC curves for neural networks trained to predict FII, FV, FVII, FVIII, FIX, FX, FXI, and FXII deficiencies from PT parameters alone, from APTT parameters alone, or from combined APTT and PT parameters;

20       Figure 22 shows the constituency of the training and cross-validation sets with regard to each factor deficiency;

Figure 23 shows results of classification of coagulation factor deficiencies as determined from  
25       area under ROC curves;

Figure 24 shows areas under ROC curves for three networks trained to classify factor deficiencies based on three different diagnostic cutoffs;

30       Figure 25 shows results from linear regressions comparing factor concentrations estimated using neural network with measured factor concentrations;

-9-

Figure 26 shows the correlation between neural network output and measured fibrinogen concentration for cross-validation data set from neural networks trained to estimate fibrinogen concentration;

5        Figure 27 shows the correlation between neural network output and measured FX concentration for cross-validation data set from neural networks trained to estimate FX concentration;

10       Figure 28 shows SOM contour plots derived from APTT optical data for the six specimen categories;

Figure 29 shows contour plots for self-organizing feature maps trained with PT data;

15       Figure 30 shows the sensitivity, specificity, efficiency and predictive value of positive test (PPV) and the predictive value of negative test (NPV), based on either APTT or PT parameters;

Figure 31 is a chart illustrating key aspects of the present invention;

20       Figure 32 is a graph of True Positive Proportion vs. False Positive Proportion for a PT assay; and

Figure 33 is a graph of True Positive Proportion vs. False Positive Proportion for an APTT assay.

25

#### DESCRIPTION OF THE PREFERRED EMBODIMENTS

In the present invention, both a method and apparatus are provided for predicting the presence of at least one congenital or acquired imbalance or therapeutic condition. As can be seen in Figure 31, one or more time-dependent measurements (101) are performed on an unknown sample (103). The term "time-

30

-10-

dependent measurement" is referred to herein to include measurements derived from assays (e.g. PT, APTT, fibrinogen, protein C, protein S, TT, ATIII, plasminogen and factor assays). The terms "unknown sample" and "clinical sample" refer to a sample, such as one from a medical patient (100), where a congenital or acquired imbalance or therapeutic condition associated with thrombosis/hemostasis is not known (or, if suspected, has not been confirmed). In the present invention, a coagulation property is measured over time so as to derive a time-dependent measurement profile. In a preferred embodiment, the time-dependent measurement is an optical measurement for deriving an optical profile. For example, a PT profile, a fibrinogen profile, a TT profile, an APTT profile and/or variations thereof can be provided where, an unknown sample is analyzed for clot formation based on light transmittance over time through the unknown sample. In another preferred embodiment, two (or more) optical profiles are provided, such as both a PT profile and an APTT profile.

After the time-dependent measurement profiles are provided, a set of predictor variables are defined (110) which sufficiently define the data of the time-dependent profile. One or more predictor variables comprise the set. And, in one embodiment, three or more, and in a preferred embodiment, four or more predictor variables were found to desirably make up the set. It was found that the characteristics of the time-dependent measurement profile could best be defined by one or more predictor variables, including the minimum of the first derivative of the optical profile, the time index of this minimum, the minimum of the second derivative of the optical profile, the time index of this minimum, the maximum of the second

-11-

derivative, the time index of this maximum, the overall change in transmittance during the time-dependent measurement, clotting time, slope of the optical profile prior to clot formation, and slope of the optical profile after clot formation.

After defining the set of predictor variables, a model (113) is derived which represents the relationship between a congenital or acquired imbalance or therapeutic condition and the set of predictor variables. This model can be derived from a neural network in one embodiment of the present invention. In another embodiment, the model is derived via a set of statistical equations.

Neural networks represent a branch of artificial intelligence that can be used to learn and model complex, unknown systems given some known data (115) from which it can train. Among the features of neural networks that make them an attractive alternative for modeling complex systems are :

1. They can handle noisy data well and recognize patterns even when some of the input data are obscured or missing.
2. It is unnecessary to determine what factors are relevant a priori since the network will determine during the training phase what data are relevant, assuming there are at least some meaningful parameters in the set.

Neural networks are formed from multiple layers of interconnected neurons like that shown in Figure 1. Each neuron has one output and receives input  $i_1, \dots, i_n$  from multiple other neurons over connecting links, or synapses. Each synapse is associated with a synaptic weight,  $w_j$ . An adder  $\Sigma$  or linear combiner sums the products of the input signals and synaptic weights

-12-

$i_j * w_j$ . The linear combiner output  $sum$ , and  $\theta$ , (a threshold which lowers or a bias which raises the output) are the input to the activation function  $f()$ . The synaptic weights are learned by adjusting their values through a learning algorithm.

After deriving the model (113), whether based on neural networks or statistical equations, the model is utilized to predict (120) the existence of a congenital or acquired imbalance or therapeutic condition in the unknown sample relative to the time-dependent measurement profile(s). As such, a congenital or acquired imbalance or therapeutic condition can be predicted. Conditions which can be predicted as being abnormal in the present invention can include, among others, a) factor deficiencies, e.g. fibrinogen, Factors II, V, VII, VIII, IX, X, XI and XII, as well as ATIII, plasminogen, protein C, protein S, etc., b) therapeutic conditions, e.g. heparin, coumadin, etc., and c) conditions such as lupus anticoagulant. In one embodiment of the present invention, the method is performed on an automated analyzer (90). The time-dependent measurement profile, such as an optical data profile, can be provided automatically by the automated analyzer, where the unknown sample is automatically removed by an automated probe from a sample container to a test well, one or more reagents are automatically added to the test well so as to initiate the reaction within the sample. A property over time is automatically optically monitored so as to derive the optical profile. The predicted congenital or therapeutic condition (120) can be automatically stored in a memory (122) of an automated analyzer and/or displayed (124) on the automated analyzer, such as on a computer monitor, or printed out on paper. As a further feature of the invention, if the predicted congenital

-13-

or acquired imbalance or therapeutic condition is an abnormal condition (126), then one or more assays for confirming the existence of the abnormal condition are performed on the automated analyzer. In fact, in a preferred embodiment, the one or more confirming assays are automatically ordered and performed on the analyzer once the predicted condition is determined, with the results of the one or more confirming assays being stored in a memory (131) of the automated analyzer and/or displayed (133) on the analyzer. Also, where the unknown sample is from a medical patient, both the derived model and other patient medical data (95) can be used for predicting the imbalance/condition. If a monitoring system is used, a plurality of optical measurements at one or more wavelengths can be taken over time so as to derive the optical profile, with the optical measurements corresponding to changes in light scattering and/or light absorption in the sample. Also, the plurality of optical measurements can each be normalized to a first optical measurement. If the time-dependent measurement is an optical profile, this can be provided automatically by an analyzer, where a sample is automatically removed by an automated probe from a sample container to a test well, one or more reagents are automatically added to the test well so as to initiate the property changes within the sample, and the development of the property over time is automatically optically monitored so as to derive the optical data profile. And, the predictor variables can be a plurality of variables, three or more predictor variables, or more than three predictor variables.

35 EXAMPLE 1: Prediction of Heparin in Sample

-14-

This example shows a set of predictor variables that adequately describe screening assay optical profiles, develops an optimal neural network design, and determines the predictive capabilities of an abnormal condition associated with thrombosis/hemostasis (in this case for the detection of heparin) with a substantial and well-quantified test data set.

Simplastin™ L, Platelin™ L, calcium chloride solution (0.025 M), imidazole buffer were obtained from Organon Teknika Corporation, Durham, NC, 27712, USA. All plasma specimens were collected in 3.2% or 3.8% sodium citrate in the ratio of one part anticoagulant to nine parts whole blood. The tubes were centrifuged at 2000 g for 30 minutes and then decanted into polypropylene tubes and stored at -80°C until evaluated. 757 specimens were prepared from 200 samples. These specimens were tested by the following specific assays: FII, FV, FVII, FVIII, FIX, FX, FXI, FXII, heparin, fibrinogen, plasminogen, protein C, and AT-III. Samples represented normal patients, a variety of deficiencies, and therapeutic conditions. Of the specimen population 216 were positive for heparin determined by a heparin concentration greater than 0.05 units/ml measured with a chromogenic assay specific for heparin. The remaining specimens, classified as heparin-negative, included normal specimens, a variety of single or multiple factor deficiencies, and patients receiving other therapeutic drugs. Positive heparin samples ranged to 0.54 units/ml.

PT and APTT screening assays were performed on each specimen utilizing two automated analyzers (MDA™ 180s) and multiple reagent and plasma vials (Organon Teknika Corporation, Durham NC 27712, USA ) over a

-15-

period of five days. When clot-based coagulation assays are performed by an automated optically-based analyzer such as the MDA 180, data are collected over time that represents the normalized level of light transmission through a sample as a clot forms (the optical profile). As the fibrin clot forms, the transmission of light is decreased. The optical profile was stored from each test.

The network configuration chosen, a multilayer perceptron (MLP) maps input predictor variables from the PT and APTT screening assays to one output variable (see Figure 2) which represents a single specified condition. A similar network was also employed for PT-only variables and APTT-only variables. This specific MLP consists of three layers: the input layer, one hidden layer, and the output layer.

A normal optical profile is shown in Figure 3. The set of predictor variables were chosen with the intent of describing optical profiles as completely as possible with a minimum number of variables. They are summarized in Table 1 where  $t$  is time from initiation of reaction,  $T$  is normalized light transmission through the reaction mixture, and  $pv_{jk}$  is the  $k$ th predictor variable of assay  $j$ .

The predictor variables were scaled to values between 0 and 1, based on the range of values observed for each variable for assay type  $k$

-16-

$$i_j = f\left(pv_{jk}, \left(pv_{j-n,k}\right)_{\min}, \left(pv_{j-n,k}\right)_{\max}\right).$$

The input variable set includes  $i_{1...7}$  for both a PT assay and APTT assay for each specimen. For known  
5 output variable values, heparin samples with results of greater than 0.05 units/ml were considered positive and assigned a value of 1 while negative samples were assigned a value of 0.

10 As the ratio of training set sample to the number of weights in a network decreases, the probability of generalizing decreases, reducing the confidence that the network will lead to correct  
15 classification of future samples taken from the same distribution as the training set. Thus, small samples sizes, then can lead to artificially high classification rates. This phenomenon is known as overtraining. In order to achieve a true accuracy rate of 80%, a guideline for the number of samples in  
20 the training set is approximately five times the number of weights in the network. For most of this work, a 14-6-1 network was used, leading to an upward bound on the sample size of  $O(450)$ . To monitor and evaluate the performance of the network and its  
25 ability to generalize, a cross-validation set is

-17-

processed at the end of each training epoch. This cross-validation set is a randomly determined subset of the known test set that is excluded from the training set.

5        Once the input predictor variables and output values were determined for all specimen optical profiles, the 757 sets of data were randomly distributed into two groups: 387 were used in the training set and 370 were used in the cross-validation  
10    set. These same two randomly determined sets were used throughout all the experiments.

      All synaptic weights and threshold values were initialized at the beginning of each training session to small random numbers.

15        The error-correction learning rule is an iterative process used to update the synaptic weights by a method of gradient descent in which the network minimizes the error as pattern associations (known input-output pairs) in the training set are presented  
20    to the network. Each cycle through the training set is known as an epoch. The order or presentation of the pattern associations was the same for all epochs. The learning algorithm consists of six steps which make up the forward pass and the backward pass. In  
25    the forward pass, the hidden layer neuron activations are first determined

-18-

$$h = F(iW1 + \theta_h)$$

where  $h$  is the vector of hidden-layer neurons,  $i$  the vector of input-layer neurons,  $W1$  the weight matrix between the input and hidden layers, and  $F()$  the activation function. A logistic function is used as the activation function

$$F(x) = \frac{1}{1 + e^{-x}}$$

10

Then the output-layer neurons are computed

$$o = F(hW2 + \theta_o)$$

15 where  $o$  represents the output layer,  $h$  the hidden layer and  $W2$  the matrix of synapses connecting the hidden layer and output layers. The backward pass begins with the computation of the output-layer error

20  $e_o = (o - d),$

where  $d$  is the desired output. If each element of  $e_o$  is less than some predefined training error tolerance

-19-

vector  $TE_{\omega}$ , than the weights are not updated during that pass and the process continues with the next pattern association. A training error tolerance of 0.1 was used in all experiments unless otherwise  
 5 specified. Otherwise, the local gradient at the output layer is then computed:

$$g_o = \alpha(1 - o)e_o.$$

10 Next, the hidden-layer local gradient is computed:

$$g_h = h(1 - h)W2g_o.$$

Once the hidden layer error is calculated, the second  
 15 layer of weights is adjusted

$$W2_m = W2_{m-1} + \Delta W2$$

where

20

$$\Delta W2 = \eta h g_o + \gamma \Delta W2_{m-1}$$

-20-

is the learning rate,  $\gamma$  is the momentum factor, and  $m$  is the learning iteration. The first layer of weights is adjusted in a similar manner

5

$$W1_m = W1_{m-1} + \Delta W1$$

where

$$\Delta W1 = \eta e + \gamma \Delta W1_{m-1}.$$

10

The forward pass and backward pass are repeated for all of the pattern associations in the training set, referred to as an epoch, 1000 times. At the end of each epoch, the trained network is applied to the cross-validation set.

15

Several methods were employed to measure the performance of the network's training. Error,  $E$ , for each input set was defined as

20

$$E = \sqrt{\frac{1}{N} \sum_{q=1}^N (d_q - o_q)^2}.$$

-21-

The learning curve is defined as the plot of  $E$  versus epoch. The percent classification,  $\varphi$ , describes the percent of the total test set (training and cross-validation) that is correctly classified based on some  
5 defined decision boundary,  $\beta$ . Receiver-Operating Characteristic (ROC) plots have also been utilized to describe trained networks' ability to discriminate between the alternative possible outcome states. In these plots, measures of sensitivity and specificity  
10 are shown for a complete range of decision boundaries. The sensitivity, or true-positive fraction is defined as

$$\text{sensitivity} = \frac{\text{true positive}}{\text{true positive} + \text{false negative}}$$

15

and the false-positive fraction, or (1-specificity) is defined as

$$(1 - \text{specificity}) = \frac{\text{false positive}}{\text{false positive} + \text{true negative}}$$

20

These ROC plots represent a common tool for evaluating clinical laboratory test performance.

-22-

Using the test set described, experiments were performed to determine if the presence of heparin could be predicted with this method. First, experiments were conducted to determine optimal error-correction backpropagation learning parameters: (1) hidden layer size, (2) learning rate, and (3) momentum. Additional experiments were also conducted to compare the performance of networks based on PT and APTT assays alone with that of one combining the results of both, the effect of the training error tolerance, and the decision boundary selection.

Figure 9 shows the effect of the hidden layer size on the training and cross validation error and the percent correct classification for the optimal decision boundary, defined as the decision boundary which yielded the lowest total number of false positives and false negatives from the total test set. As the hidden layer size is increased, the error is decreased. However, the ability to generalize does not increase after a hidden layer size of 6. The most significant benefit in terms of both error and percentage correct classification is between 4 and 6. A hidden layer size of 6 was used for the remainder of the experiments.

A series of experiments were conducted with  $\eta = \{0.01, 0.1, 0.5, 0.9\}$  and  $\gamma = \{0.0, 0.1, 0.5, 0.9\}$ . Figure 4 shows the learning curves for two of the best

-23-

combinations of parameters. Figure 5 shows an example learning curve when the learning rate is so high it leads to oscillations and convergence to a higher  $E$ . In general, as  $\eta \rightarrow 0$  the network converged to a lower  $E$  and as  $\gamma \rightarrow 1$ , the rate of convergence improved. As  $\eta \rightarrow 1$ , the value of  $E$  converged too increased and oscillations increased. In addition, as  $\eta \rightarrow 1$ ,  $\gamma \rightarrow 1$  exacerbated the oscillations.

Figure 6 shows a comparison of the learning curve for the training set and cross-validation set for  $\eta=0.5$  and  $\gamma=0.1$ . It is a primary concern when developing neural networks, and it has been previously shown that it is important to look not only at the error in the training set for each cycle, but also the cross-validation error.

Figure 7 shows the learning curve  $\eta=0.5$  and  $\gamma=0.1$  and a learning tolerance of 0.0 and 0.1. These results suggest that a small learning tends to smoothen the convergence of the learning process.

Figure 8 shows the ROC plot for networks trained with the predictor variables from each of the two screening assays with that of them combined. In the single assay cases, the hidden layer size was 3. While using the data from one assay does lead to some success, using the information from both assays makes

-24-

a significant improvement in the ability of the network to correctly predict the presence of heparin. This graph indicates that a 90% true positive proportion can be achieved with a false positive proportion of 15%. Using a single assay, a 60-70% true positive proportion can be achieved with a false positive proportion of approximately 15%.

EXAMPLE 2: Factor VIII

10        Similar tests were run as in Example 1. As can be seen in Figures 10 and 11, two training sessions were conducted for predicting a Factor VIII condition in an unknown sample. Figure 10 is a receiver operator characteristic plot related to predicting an abnormality in relation to Factor VIII. In Figure 10, everything below 30% activity was indicated as positive, and everything above 30% was indicated as negative. Cutoff values other than 30% could also be used. In this Example, the activity percentage has a known accuracy of approximately + or - 10%. In Figure 11, the actual percent activity was utilized as the output.

EXAMPLE 3: Factor X

25        As can be seen in Figure 12, the method of the present invention was run similar to that as in Example 2, where here an abnormality in Factor X

-25-

concentration was predicted from unknown samples. Everything below 30% activity was indicated as positive, and everything above 30% was indicated as negative. Cutoff values other than 30% could also be  
5 used.

The results of the cross-validation sample sets throughout the experiments indicate that the sample size was sufficient for the network to generalize. While the random distribution of the training and  
10 cross-validation sets were held constant throughout the experiments presented, other distributions have been used. These distributions, while all yielding different results, still lead to the same general conclusion.

15 Many alternatives for or additions to the set of predictor variables were explored. This included coefficients of a curve fitted to the data profile, pattern recognition, and clot time-based parameters. Low order functions tend to lose information due to  
20 their poor fit, and high order functions tend to lose information in their multiple close solutions. Clot-based parameters, such as clot time, slope in the section prior to the initiation of clot formation, and afterwards, are often available, but not always  
25 (because in some samples, the clot time is not detectable). The successful results observed indicate that the set of predictor variables used are

-26-

effective for predicting congenital or acquired imbalances or therapeutic conditions.

The optimization of the network learning algorithm's parameters made significant differences in its performance. In general, performance was best with low learning rates, high momentum rates, some small training error tolerance, and a hidden layer size approximately half of the size of the input layer.

10

#### ADDITIONAL EXAMPLES:

Optical measurements for APTT and PT assays were performed on MDA 180 instruments at a wavelength of 580 nm. Plasma specimens (n= 200) included normal patients, patients with a variety of coagulation factor deficiencies and patients undergoing heparin or other anticoagulant therapy. Duplicate APTT and PT screening assays were performed on each specimen with two MDA 180s using single lots of APTT and PT reagents. These specimens were also analyzed using specific assays for FII, FV, FVII, FVIII, FIX, FX, FXI, FXII, heparin, fibrinogen, plasminogen, protein C and antithrombin-III.

25

*Data Processing and Neural Networks*

-27-

Optical profile data files were exported from the MDA 180s and processed off-line. A set of nine parameters was derived to describe the timing, rate and magnitude of coagulation events. These parameters were calculated for all APTT and PT tests. The parameter set is modified slightly from that for Example 1. In this approach, the optical data for a PT or APTT assay was divided into three segments (a pre-coagulation segment, a coagulation segment and a post-coagulation segment) using divisions based on the minimum and maximum value of the second derivative for changes in optical signal with respect to time. The parameters that were analyzed included: (1) the times at which the onset, midpoint and end of the coagulation phase occur ( $t_{min2}$ ,  $t_{min1}$  and  $t_{max2}$ ; respectively); (2) mean slopes for the pre-coagulation phase and the post-coagulation phase ( $slope1$  and  $slope3$ , respectively) and the slope at the mid-point of coagulation ( $min1$ , the coagulation "velocity" at reaction midpoint, which is analogous to  $slope2$ ); (3) terms for coagulation "acceleration" and "deceleration" ( $min2$  and  $max2$ , respectively); and (4) the magnitude of signal change during coagulation ( $\delta$ ).

Three different sets of data parameters were used as input to the neural network: (1) the nine parameters from PT assays, (2) the nine parameters

-28-

from APTT assays, and (3) the combined parameters from the APTT and PT assays. Each specimen was run in duplicate on two instruments, to give a total of approximately 800 parameter sets from the 200  
5 specimens. The total number varied slightly because of missing data due to insufficient sample, mechanical failure or unspecified failures. The data parameter sets were divided into training and cross-validation sets randomly by specimen where all replicates for a  
10 given specimen were grouped either in the cross-validation set or training set. The same training and cross-validation sets were used throughout this study. The method for training and cross-validation of the back-propagation neural networks has been described in  
15 relation to Example 1. Each neural network was trained for 1000 epochs. Training parameters were learning rate, 0.01; momentum, 0.5; learning tolerance, 0.10; decay, 0.05; input layer size, 18 (or 9 for single assays); hidden layer size, 9 (or 5 for single  
20 assays); and output layer size, 1. Three types of networks were trained. These included networks that classified specimens as deficient or non-deficient based on a single diagnostic cut-off, sets of networks that used diagnostic cut-offs at different levels of  
25 the same factor, and networks trained to estimate the actual concentration of a specific factor.

-29-

*Classification of Factor Deficiencies Based on a  
Single Diagnostic Cut-off Level*

In the first set of tests, neural networks were trained to classify plasma samples into two groups, positive (factor-deficient) and negative (non-deficient), and results were compared to classification based on the measured factor concentration for the specimens. In most testing, the diagnostic cut-off for defining factor deficiencies was set as 30%; that is, specimens with a measured concentration of less than 30% of normal for a specific factor were defined as deficient and those with greater than 30% activity were defined as non-deficient. These diagnostic cut-off levels were arbitrarily defined, but are based on clinical requirements and reagent sensitivity. The desired output from positive samples and negative samples were defined as '1' and '0', respectively; the actual output for each specimen was a floating point value,  $a$ , where  $0 \leq a \leq 1$ . Figure 22 shows the constituency of the training and cross-validation sets with regard to each factor deficiency. Classification of specimens was evaluated at varying "decision boundaries" that divided the neural network outputs into positive and negative groups. This positive or negative classification was then compared to the desired output (the known classification) for each input data set. Results were plotted as nonparametric receiver-operating

-30-

characteristic (ROC) curves and the areas under the curves were computed along with their associated standard errors. ROC curves were also derived for APTT and PT clot time values for comparison. Data points on the ROC curves represent the proportion of true-positive and false-positive classifications at various decision boundaries. Optimum results are obtained as the true-positive proportion approaches 1.0 and the false-positive proportion approaches 0.0 (upper-left corner of graph). The optimum global measure of the ROC curve is an area of 1.0.

#### *Classification of Factor Deficiencies at Multiple Diagnostic Cut-off Levels*

A second set of networks was trained for FX classification in a similar manner to the first set except that the diagnostic cut-off level was varied (10%, 30%, and 50%). FX was chosen for this experiment because the data set contained a greater number of positive samples at all cut-off levels than other factors.

#### *Estimation of Factor Concentration Using Neural Networks*

A third set of networks were trained to approximate actual specific factor activities (FII, FV, FVII, FVIII, FIX, FX, FXI and FXII) and fibrinogen levels from

-31-

combined PT and APTT parameters from unknown samples. In these cases, the desired output of the training and cross-validation sets was the measured activity for a specific factor for each specimen and the actual output of the neural network was a predicted concentration for this specific factor activity. The coefficients of linear regressions using the desired outputs versus the actual neural network outputs for the cross-validation set were used to describe the performance of these networks. The Pearson product moment correlation coefficient,  $r$ , was used to estimate the correlation between the two data sets.

*Classification of Factor Deficiencies Based on a  
Single Diagnostic Cut-off Level*

Neural networks were trained to classify samples as deficient (positive result) or non-deficient (negative result) for individual plasma factors, using a value of 30% activity as the diagnostic cut-off to define deficiencies. Results were examined graphically using receiver-operating curves (ROC). These graphs plot the true-positive proportion (number of positives detected divided by the total number of positives) versus the false-positive proportion (number of negative specimens incorrectly diagnosed as positive divided by the total number of negatives). An ROC curve is generated by determining true-positive and false-positive proportions

-32-

at different "decision boundaries" for the diagnostic test. For example, an ROC plot for diagnosis of FII deficiencies using PT clot time was generated by varying the decision boundary (value of PT clot time) used to

5 differentiate between deficient and non-deficient specimens. When a short clot time is used as the decision boundary, most deficient specimens can be identified but a significant proportion of non-deficient specimens may also be flagged (false-positives). When

10 a long clot time is used as the decision boundary, the proportion of false-positives decreases, but the number of true-positive specimens that are not diagnosed may also increase. Under ideal conditions, a decision boundary can be identified from an ROC curve that

15 produces a very high proportion of true-positives and a very low proportion of false-positives. This condition corresponds to the upper left region of the ROC plot. Two related terms that are often applied to clinical diagnostic tests are "sensitivity" and "specificity".

20 Sensitivity refers to the ability to detect positive specimens and corresponds to the y-axis of the ROC plots. Specificity refers to the proportion of specimens diagnosed as negative which are correctly identified. The ROC x-axis equals  $(1 - \text{specificity})$ .

25 Visual assessment of the ROC curves is one method used to evaluate the performance of the neural networks and compare them to the diagnostic power of PT and APTT clot

-33-

times. Another method is to measure the diagnostic performance by using the area under the ROC curves. The area under the ROC curve is equivalent to an estimate of the probability that a randomly chosen positive specimen  
5 will have a more positive result than a randomly chosen negative specimen. In the event that ROC curves overlap, the shape of the curves as well as the areas beneath them becomes important. An ROC curve encompassing a smaller area may be preferable to an  
10 overlapping curve with greater area depending on the desired performance for a given diagnostic system.

Figures 14 - 21 show ROC curves for neural networks trained to predict FII, FV, FVII, FVIII, FIX, FX, FXI, and FXII deficiencies from PT parameters alone, from  
15 APTT parameters alone, or from combined APTT and PT parameters. ROC plots based on classification using APTT and PT clot times are included for comparison. Figure 23 shows the area under these curves and their associated standard errors.

20 Results for classification of FII deficiencies are shown in Figure 14. Best results were observed for neural networks using APTT parameters alone or combined with PT parameters, with area under ROC curves greater than 0.99 in both cases (Figure 23). Classification  
25 based on PT or APTT clot times, or from neural networks using PT data alone resulted in less successful classification and reduced area under curves.

-34-

Results from classification of FV deficiencies showed somewhat different characteristics (Figures 15 and 23). Best results were observed for classification from a neural network using APTT data parameters, based on visual inspection and area under the ROC curve. Less successful classification were obtained from neural networks using PT data parameters alone or combined with APTT data, and from PT clot time, as judged from areas under ROC curves. Classification based on PT clot time was qualitatively different from neural networks using PT data, however, and tended toward higher sensitivity rather than specificity. This type of pattern was observed for classification of several coagulation factors, especially factors VIII, X and XI. In situations where overlapping ROC curves were obtained, consideration of the relative value of specificity and sensitivity, as well as the area under ROC curves, becomes important in comparing diagnostic results.

For several of these plasma factors, including FV, FVIII, FIX, FX, FXI and FXII (Figures 15, 17, 18, 19, 20 and 21), it appeared that it would be possible to achieve a moderately high true-positive proportion ( $> 0.6$ ) while maintaining a low false-positive proportion ( $< 0.1$ ) from neural networks using PT, APTT or combined parameters. This corresponds to a situation where a significant proportion of deficient specimens are not

-35-

detected (moderate sensitivity), but those that are detected are correctly classified as deficient for that specific factor (high specificity). In contrast, using PT or APTT clot times it was possible for most factors to adjust decision boundaries to identify most deficiencies (true-positive proportion approaching 1.0, high sensitivity), but with a relatively high rate of false-positives (low specificity). This corresponds to a situation where most or all deficient specimens are detected, but where the specific factor deficiency is frequently not correctly identified. The first scenario involving moderate or high true-positive rates with very low false positive rates may be preferable in the diagnostic scheme shown in Figure 13.

For factors II, V, IX and XII, it appeared that an appropriate choice of neural network gave best diagnostic performance, as judged from the area under curves. For factors VIII, X and XI, neural networks were not visibly superior to diagnosis based on clot times when areas under ROC curves were the only consideration; however, neural networks for these factors did provide better specificity. For one factor (FVII, Figure 16), neural network classification was less effective than for other factors, at least in this test system.

The performance of networks using data parameters from PT or APTT assays alone or in combination varied for different factors. For factors VIII and XII, best

-36-

performance (significantly greater area with no overlap) was observed when the combined sets of APTT-PT data parameters were used. For several other factors, use of a single parameter set provided results that were comparable to or better than the combined APTT and PT parameters. A network using only APTT data parameters (APTT NN) was equivalent (similar area) to a network using combined APTT-PT data (APTT-PT NN) for FII and FX; and superior for FV (greater area and no overlap). Networks using only PT parameters provided results that were comparable (similar area) to the combined parameters for FV classification and better (greater area and insignificant overlap) for FIX classification.

The data for misclassified positive specimens were examined more closely. Misclassified positive specimens were clustered in several categories: 1) Specimens with "no clot" APTT or PT results (specimens with very prolonged or very weak coagulation reaction for which no clot time can be reliably calculated); 2) specimens with multiple deficiencies or abnormalities; 3) specimens with borderline deficiencies (factor activity marginally lower than the diagnostic cut-off of 30%); and 4) specimens with atypically steep slope during the pre-coagulation phase for APTT assays that were not characteristic of other specimens in the same classification (FX deficiencies were not detected for

-37-

two specimens exhibiting this characteristic with FX activities of 26.8% and 16.8%, respectively).

#### *Classification of Factor Deficiencies at Multiple 5 Diagnostic Cut-off Levels*

The ability of neural networks to classify FX-deficient specimens was tested at varying diagnostic cut-offs. Areas under the ROC curves for cut-off levels of 10%, 30% and 50% FX activity are shown in  
10 Figure 24. Results indicate that progressively poorer classification (as expressed in smaller areas under ROC curves) was observed as higher cut-off levels were used.

This was true for classification based on neural networks or PT clot times.

15

#### *Neural Network Estimation of Factor Concentration*

Neural networks were also trained to estimate actual protein concentrations (as opposed to a positive/negative classification at a defined cut-off)  
20 for FII, FV, FVII, FVIII, FIX, FX, FXI, FXII and fibrinogen. Linear correlation coefficients for the estimated and measured concentrations are shown in Figure 25 for all experiments, and plots of the correlation data are shown in Figure 26 for fibrinogen  
25 and Figure 27 for FX. Correlation data between PT and APTT clot time and measured concentrations are also shown in Figure 25 for comparison.

-38-

*Example: Self-Organizing Feature Maps*

Neural networks using self-organizing feature maps and learning vector quantization were used to analyze optical data from clinical coagulation tests. Self-organizing feature maps using an unsupervised learning algorithm were trained with data from normal donors, patients with abnormal levels of coagulation proteins and patients undergoing anticoagulant therapy. Specimen categories were distinguishable in these maps with varying levels of resolution. A supervised neural network method, learning vector quantization, was used to train maps to classify coagulation data. These networks showed sensitivity greater than 0.6 and specificity greater than 0.85 for detection of several factor deficiencies and heparin.

An alternative approach to analyzing PT and APTT data with artificial neural networks (as set forth in Example 1) is by using self-organizing feature maps. Self-organizing feature maps contain layers of input and output neurons only and contain no hidden layers. Training is based on competitive learning where the output neurons compete with one another to be activated and only one output neuron is activated for any given set of inputs. Output neurons become selectively tuned to certain input patterns, and data with similar features tend to be grouped together spatially. This type of neural network may use either an unsupervised or

-39-

supervised learning algorithm. When an unsupervised method is used, such as the self-organizing map (SOM) algorithm, unidentified input patterns are presented to the network during training and the output for each  
5 input pattern is the coordinates of the winning neuron in the output layer, or map. When a supervised method is used, such as learning vector quantization (LVQ), input patterns are presented along with a known sample classification to the network during training and the  
10 output is a unique predicted classification. The LVQ method is similar to SOM, except that the map is divided into classes, and the algorithm attempts to move outputs away from the boundaries between these classes.

MDA Simplastin L (PT reagent), MDA Platelin L (APTT  
15 reagent) and other reagents were obtained from Organon Teknika Corporation, Durham, NC 27712, USA, unless otherwise indicated. Factor-deficient plasmas for factor assays were obtained from Organon Teknika and George King Bio-Medical Corporation, Overland Park,  
20 Kansas 66210, USA. Additional factor-deficient plasmas were obtained from HRF, Raleigh, NC 27612, USA. Random samples, specimens from patients receiving heparin or oral anticoagulant therapy, and other specimens were obtained from Duke University Medical  
25 Center Coagulation Laboratory.

All testing was performed on MDA 180 coagulation analyzers (Organon Teknika). Optical measurements for PT

-40-

and APTT assays were performed at a wavelength of 580 nm. Plasma specimens (n= 200) included normal patients, patients with a variety of deficiencies, and patients undergoing heparin or other anticoagulant therapy.

5 Duplicate PT and APTT assays were performed on each specimen using two MDA 180s to give a total of approximately 800 parameter sets from the 200 specimens. The total number varied slightly because of missing data due to insufficient sample, mechanical failure or

10 unspecified failures. These specimens were also tested to determine the concentration of coagulation factors (FII, FV, FVII, FVIII, FIX, FX, FXI, FXII) heparin, and fibrinogen. The diagnostic cut-off for defining factor deficiencies was set at 30%; that is, specimens with a

15 measured concentration of less than 30% of normal for a specific factor were defined as deficient and those with greater than 30% activity were defined as non-deficient. Samples were defined as positive for heparin if the measured heparin concentration was greater than 0.05

20 IU/ml.

#### *Optical Data Processing*

Optical profile data files were exported from MDA 180s and processed off-line. A set of nine parameters

25 was derived to describe the timing, rate and magnitude of coagulation events for PT and APTT tests, as described previously. In this approach, the optical

-41-

data for a PT or APTT assay was divided into three segments (a pre-coagulation segment, a coagulation segment and a post-coagulation segment) using divisions based on the minimum and maximum value of the second derivative for changes in optical signal with respect to time. Parameters included: 1) the times at which the onset, midpoint and end of the coagulation phase occur; 2) mean slopes for the pre-coagulation phase and the post-coagulation phase and the slope at the mid-point of coagulation; 3) terms for coagulation "acceleration" and "deceleration"; and 4) the magnitude of signal change during coagulation.

#### *Self-Organizing Map Algorithm*

A self-organizing feature map neural network consists of input and output layers of neurons. The self-organizing map (SOM) algorithm transforms an input vector (a set of data parameters from PT or APTT optical data for a single test) to an individual output neuron whose location in the output layer, or map, corresponds to features of the input data. These features tend to be spatially correlated in the map. There are five steps in the SOM learning process:

1. Unique weight vectors  $w_j(0)$ , are randomly chosen.
2. A sample from the training set is selected.
3. The best-matching winning neuron  $i(x)$  at time  $n$ , using the minimum-distance Euclidean criterion

-42-

$$i(x) = \arg \min_j \{ \|x(n) - w_j(n)\| \}$$

is identified.

4. The weight vectors of all neurons are updated with  
5 the formula

$$w_j(n+1) = \begin{cases} w_j(n) + \alpha(n)[x(n) - w_j(n)], & j \in N_c(n) \\ w_j(n), & j \notin N_c(n) \end{cases}$$

10 where  $\alpha(n)$  is the learning rate parameter, and  $N_c(n)$   
is the neighborhood function centered around the  
winning neuron  $i(x)$ ; both  $\alpha(n)$  and  $N_c(n)$  vary  
dynamically during training.

5. Steps 2 through 4 are repeated until the map  
reaches equilibrium.

15

The SOM tests were performed using the Self-Organizing Map Program Package (SOM\_PAK) available from the Helsinki University of Technology, Laboratory of Computer Sciences. Two different sets of parameters  
20 were used as input to the SOMs: (1) the nine parameters from a PT assay, and (2) the nine parameters from the APTT assay. All data sets (786) were used to train the SOMs. A 10x10 map was trained using a hexagonal neighborhood in two stages. In the first stage, the map  
25 was trained for 1000 epochs (an epoch is one cycle through all data sets) with an initial learning rate

-43-

parameter of 0.5 (decreasing linearly to zero during training) and a neighborhood radius of 10 (decreasing linearly to 1 during training). In the second stage, the map was trained for 10000 epochs using a learning rate parameter of 0.1 and a radius of 3.

### *Learning Vector Quantization*

Learning vector quantization (LVQ) is a supervised learning algorithm often used to fine-tune self-organizing feature maps in order to use them in the role of a pattern classifier. The classification accuracy of the map is improved by pulling the weight vectors away from the decision surfaces that demarcate the class borders in the topological map. There are several variations of the LVQ algorithm; the one used here is referred to as LVQ1. The learning process is similar to the SOM algorithm described above, except that known sample classifications are included when weight vectors are updated (step 4):

1. Initial weight vectors  $w_j(0)$ , are randomly chosen.
2. A sample from the training set with a known classification is selected.
3. The best-matching winning neuron  $i(x)$  at time  $n$ , using the minimum-distance Euclidean criterion

25

$$i(x) = \arg \min_j \{ \|x(n) - w_j(n)\| \}$$

-44-

is identified.

4. The weight vectors of all neurons are updated with the formula

$$5 \quad w_j(n+1) = \begin{cases} w_j(n) + \alpha(n)[x(n) - w_j(n)], & j=i, C_{w_i} = C_x \\ w_j(n) - \alpha(n)[x(n) - w_j(n)], & j=i, C_{w_i} \neq C_x \\ w_j(n), & j \neq i \end{cases}$$

where  $C_{w_i}$  is the class associated with the vector  $w_i$  and  $C_x$  is the class associated with the input vector  $x$ .

- 10 5. Steps 2 through 4 are repeated until the map reaches equilibrium.

The LVQ tests were performed using the Learning Vector Quantization Program Package (LVQ\_PAK), also available from the Helsinki University of Technology, Laboratory of Computer Sciences. The sets of parameters from the APTT assay or PT assays were used for the LVQ networks. The data parameter sets were divided evenly into training and cross-validation sets randomly by specimen, where all replicates for a given specimen were grouped either in the cross-validation set or training set. The same training and cross-validation sets were used throughout this study. The LVQ networks were trained to classify plasma samples into two categories, positive (factor-deficient specimens or specimens from patients undergoing anticoagulant therapy) and negative (non-deficient or no anticoagulant therapy), and results

-45-

were compared to classification based on the measured factor concentration or therapeutic condition for the specimens. LVQ training was performed using 200 weight vectors, 10000 epochs, initial learning rate parameter  
5 of 0.5 (decreasing linearly to 0), and 7 neighbors used in knn-classification.

LVQ networks were evaluated using sensitivity (the proportion of known positive specimens that were correctly classified as positive by the network),  
10 specificity (the proportion of known negative specimens that were correctly classified as negative by the network), positive predictive value (PPV), negative predictive value (NPV) and efficiency. These terms are defined below, where TP, TN, FP and FN correspond to  
15 true positive, true negative, false positive and false negative classifications, respectively.

$$\text{sensitivity} = \frac{TP}{TP + FN}$$

$$\text{specificity} = \frac{TN}{FP + TN}$$

-46-

$$PPV = \frac{TP}{TP + FP}$$

5

$$NPV = \frac{TN}{TN + FN}$$

10

$$efficiency = \frac{TN + TP}{TP + FP + FN + TN}$$

15

### Self-Organizing Map Algorithm

Self-organizing feature maps were trained using optical data parameters from either PT or APTT data for 200 specimens as input. Network output consisted of map coordinates for each specimen. Contour plots were constructed for six categories of known specimen classifications: normal donors, specimens with heparin > 0.05 IU/ml, fibrinogen >600mg/dl, fibrinogen <200 mg/dl, patients receiving oral anticoagulants, and 25 factor-deficient specimens (specimens with <30% of

-47-

normal activity for FII, FV, FVII, FVIII, FIX, FX, FXI, or FXII). These contour plots depict the distribution of specimens within a category according to their map coordinates.

- 5           Figure 28: Contour plots for populations of samples used in training a self-organizing feature map using the unsupervised training method SOM based on data from APTT assays. Optical data parameters from 765 APTT assays were used to train this self-organizing feature map.
- 10       The shaded areas represent the distribution of output neurons for specific specimen populations within the feature map. Each contour line represents an incremental step of one test result located at a given set of map coordinates.
- 15           Figure 28 shows SOM contour plots derived from APTT optical data for the six specimen categories. Specimens containing low fibrinogen and high fibrinogen were classified at opposite borders of the SOM with no overlap. Normal populations showed some overlapping
- 20       with low fibrinogen, factor deficient and oral anticoagulated categories. Overlap between normal specimens and edges of the high and low fibrinogen populations is expected, since some proportion of healthy donors have fibrinogen levels that are lower or
- 25       higher than normal. Overlap between mapping of normal specimens and factor-deficient plasmas is also not surprising, since APTT tests are sensitive to some

-48-

factor-deficiencies (but not others), whereas PT assays are sensitive to a separate subset of factor deficiencies. The low fibrinogen category tended to overlap the factor-deficient category, consistent with  
5 our observation that many factor-deficient specimens also had reduced fibrinogen levels. The heparin category tended to overlap the high fibrinogen category, again consistent with measured levels of fibrinogen for these specimens. Little or no overlap was observed  
10 between normal specimens and specimens containing heparin. Specimens from patients receiving oral anticoagulant therapy show significant overlap with both normal and heparin populations. This is consistent with known properties of APTT assays, which are sensitive to  
15 heparin therapy but relatively insensitive to oral anticoagulant therapy.

Figure 29: Contour plots for populations of samples used in training a self-organizing feature map using the unsupervised training method SOM based on optical data  
20 from 765 PT assays. Experimental details are as described in the Materials and Methods section and in Figure 28.

Contour plots for self-organizing feature maps trained with PT data are shown in Figure 29. Results  
25 are similar to maps from APTT data in several respects: (1) high and low fibrinogen were well resolved at opposite sides of the map; (2) normal specimens were

-49-

localized in a region that overlapped low fibrinogen specimens slightly; (3) factor-deficient specimens were distributed between non-overlapping regions and regions that overlapped low fibrinogen and normal populations.

5   Overlap was consistent with measured fibrinogen for some specimens, and with poor sensitivity of PT reagents to some factor deficiencies in other cases; (4) oral anticoagulated specimens showed some overlap with both normal and heparin populations; and (5) the heparinized

10   population was distributed over a large portion of the map. Overlap between heparinized specimens and high fibrinogen populations was consistent with measured fibrinogen levels. The resolution of the heparin population is somewhat surprising, considering that PT

15   reagents are relatively insensitive to heparin.

These results indicate that self-organizing feature maps are capable of distinguishing differences in optical data parameters from APTT and PT assays even when no information regarding specimen diagnosis is

20   presented to the neural network. Resolution of specimen populations was variable, depending on reagent properties and sensitivities, and on whether specimens belonged to a given category uniquely or to multiple overlapping categories.

25   Example

-50-

The following procedure was performed for PT assays (see Figure 32) and then separately for APTT assays (see Figure 33).

For Clot Time:

- 5        1. Calculate mean and standard deviation (SD) for clot time from assays (PT or APTT) run on aliquots from normal specimens (n = 79).
- 10       2. Calculate z-scores for clot times from the normal group in step from the normal group in step 1 (n = 79) and a group from assays performed on aliquots from abnormal specimens (n=410). The group of abnormals included various factor deficiencies, oral-anticoagulated specimens, suspected DIC specimens, and heparinized specimens. Z-scores are calculated by  
15 subtracting the mean of normals from the clot time and then dividing the result by the SD.
- 20       3. Determine the number of true positives, true negatives, false positives and false negatives if specimens with an absolute value of the z-score greater than x SD (where x=1,2,3,4,5,) are called positive.

For parameters:

- 25       1. Calculate Mean and SD for each of the nine parameters (slope\_1, slope\_3, delta, index\_min\_1, min\_1, index\_max\_2, max\_2, index\_min\_2, min\_2) from assays (PT or APTT) run on aliquots from normal specimens (n=79).

-51-

2. Calculate z-scores for each parameter of each specimen from the normal group (n=79) and abnormal group (n=410).

3. Determine the number of true positives, true negatives, false positives and false negatives if specimens with an absolute value of the z-score greater than  $x$  SD (where  $x=1,2,3,4,5$ ) for one or more of the parameters are called positive.

10        Results:

Sensitivity and specificity for non-specific abnormals as a group is higher when using all parameters rather than the traditional clot time used alone. This method requires only (1) a group of known normal specimens, (2) calculation of mean and SD for each of the nine parameters of the normal group and an unknown specimen, (3) computation of z-scores for the nine parameters of the unknown specimen.

*Learning Vector Quantization*

20        Eighteen LVQ networks were trained to predict the presence or absence of a specific factor deficiency or therapeutic condition from APTT or PT optical data. Results for the cross-validation data are summarized in Figure 30. Previous studies concluded that back-  
25        propagation neural networks were capable of sensitivity  $> 0.6$  while maintaining specificity  $> 0.9$  for all factors except FVII using an appropriate choice of PT and APTT

-52-

data separately or in combination. In this study, LVQ networks using APTT data gave sensitivity  $> 0.6$  with specificity  $> 0.85$  for factors II, X, XI, and XII, and heparin. LVQ networks using PT data were able to

5 achieve  $> 0.6$  sensitivity while maintaining  $> 0.85$  specificity for Factors II, X, and XI, and heparin (Figure 30). Results from LVQ networks showed less sensitivity for prediction of FVII deficiencies, consistent with results from back-propagation networks.

10 For FV, FVIII and FIX, sensitivity for predicting deficiencies from LVQ cross-validation sets was generally less ( $< 0.35$ ) than for factors II, X, XI and XII.

It is to be understood that the invention described

15 and illustrated herein is to be taken as a preferred example of the same, and that various changes in the method and apparatus of the invention may be resorted to, without departing from the spirit of the invention or scope of the claims.

-53-

WE CLAIM:

1. A method for predicting the presence of an abnormal level of one or more proteins in the clotting cascade from at least one time-dependent measurement profile, comprising:

- a) performing at least one time-dependent measurement on an unknown sample and measuring a respective property over time so as to derive a time-dependent measurement profile;
  - 10 b) defining a set of a plurality of predictor variables which sufficiently define the data of the time-dependent measurement profile;
  - c) deriving a model that represents the relationship between the abnormal level of said one or  
15 more proteins in the clotting cascade and the set of predictor variables; and
  - d) utilizing the model of step c) to predict the existence of the abnormal level of said one or more proteins in the clotting cascade and to predict which  
20 protein or proteins in the clotting cascade are said one or more proteins which are at an abnormal level;
- the prediction of the protein or proteins at an abnormal level being a better prediction than an abnormal clot time alone.

25

2. The method of claim 1, where in the prediction of the one or more proteins at an abnormal level, the specificity is equal to or greater than 0.85.

30

3. The method of claim 2, where in the prediction of the one or more proteins at an abnormal level, the sensitivity is greater than 0.6.

-54-

4. The method of claim 2, where the one or more proteins predicted to be at an abnormal level, is one or more of Factors II, V, VII, VIII, IX, X, XI or XII.

5 5. The method of claim 3, where the one or more proteins predicted to be at an abnormal level, is one or more of Factors II, X, XI or XII.

10 6. The method of claim 2, where in the prediction of the one or more proteins at an abnormal level, the sensitivity is between 0.3 and 0.8.

15 7. The method of claim 6, where the one or more proteins predicted to be at an abnormal level is one or more of Factors VIII through XII.

20 8. The method of claim 2, wherein samples with a measured concentration of less than about 30% of normal for a specific factor are defined as being at an abnormal level.

25 9. A method according to claim 1, wherein said at least one time-dependent measurement profile is at least one optical profile.

30 10. A method according to claim 9, wherein said at least one optical profile is provided by an automated analyzer for thrombosis and hemostasis testing.

11. A method according to claim 9, wherein a plurality of optical measurements at one or more wavelengths are taken over time so as to derive said at

-55-

least one optical profile, said optical measurements corresponding to changes in light scattering and/or light absorption in the unknown sample.

5

12. A method according to claim 9, wherein a plurality of optical measurements are taken over time so as to derive said at least one optical profile, and wherein said plurality of optical measurements are each  
10 normalized to a first optical measurement.

13. A method according to claim 10, wherein in step a) said at least one optical profile is provided  
15 automatically by said analyzer, whereby said unknown sample is automatically removed by an automated probe from a sample container to a test well, one or more reagents are automatically added to said test well so as to initiate said property changes within said sample,  
20 and the development of said property over time is automatically optically monitored so as to derive said optical data profile.

25 14. A method according to claim 13, wherein after step d), a predicted congenital or acquired imbalance or therapeutic condition is automatically stored in a memory of said automated analyzer and/or displayed on said automated analyzer.

30

15. A method according to claim 13, wherein in step d), one or more assays for confirming the existence of said congenital or acquired imbalance or therapeutic  
35 condition is automatically performed.

-56-

16. A method according to claim 15, wherein said one or more confirming assays are automatically ordered and performed on said analyzer, with results of said one  
5 or more assays being stored in a memory of said automated analyzer and/or displayed on said analyzer.

17. A method according to claim 1, further  
10 comprising:  
before step a), providing a set of data from known samples, which data is used in step c) for deriving said model.

15  
18. A method according to claim 17, wherein said data from known samples is provided by performing a plurality of assays on said known samples.

20  
19. A method according to claim 1, wherein in step a), a plurality of time-dependent measurement profiles are derived for use in step b).

25  
20. A method according to claim 19, wherein said plurality of time dependent measurement profiles includes at least two profiles from assays initiated with PT reagents, APTT reagents, fibrinogen reagents and TT reagents.

30  
21. A method according to claim 1, wherein said unknown sample is a sample from a medical patient, and wherein in step d), both said model and additional patient medical data are utilized for predicting the existence of said congenital or acquired imbalance or  
35 therapeutic condition.

-57-

22. A method for presenting a relationship between data from an assay relating to thrombosis-hemostasis on an unknown sample, and data from a plurality of assays relating to thrombosis-hemostasis from known sample  
5 populations, comprising:

(a) providing data from at least one time dependent measurement profile for each of a plurality of known blood samples;

(b) performing at least one time-dependent  
10 measurement on an unknown blood sample and measuring a respective property over time so as to derive at least one time-dependent measurement profile for said unknown blood sample;

(c) transforming data from step (b) to a plurality  
15 of predictor variables which sufficiently captures the information content of both the unknown blood sample time-dependent measurement profile and the known blood sample time-dependent measurement profiles;

(d) presenting the data from said unknown blood  
20 sample time-dependent measurement profile relative to the data from said known blood sample time-dependent measurement profiles.

23. The method according to claim 22, wherein said  
25 plurality of known blood samples and said unknown blood sample are samples of whole blood, plasma, or other portion of whole blood.

24. The method according to claim 23, wherein said  
30 plurality of known blood samples are samples of which information is known relating to one or more intrinsic or extrinsic clotting factors and/or therapeutic agents.

25. The method according to claim 22, wherein steps  
35 (c) and (d) comprise transforming a set of input

-58-

parameters from the time-dependent measurement profiles for said known blood samples and said unknown blood sample, to corresponding individual output neurons whose location on an output map corresponds to the respective  
5 input data.

26. The method according to claim 25, wherein said at least one time-dependent measurement profile comprises a profile from a PT assay.

10

27. The method according to claim 25, wherein said at least one time-dependent measurement profile comprises a profile from an APTT assay.

15 28. The method according to claim 25, wherein said at least one time-dependent measurement profile is an optical profile and comprises a PT assay and an APTT assay.

20 29. The method according to claim 22, wherein said at least one time-dependent measurement profile is an optical profile based on optical transmittance.

25 30. The method according to claim 22, wherein said plurality of known blood samples are samples of which are known the presence or absence of one or more abnormalities relating to at least one of fibrinogen level, oral anticoagulant, heparin, and one or more Factor levels.

30

31. The method according to claim 22, wherein in step (d), one or more of normal sample, presence of heparin, and one or more Factor deficiencies are presented on a PT map.

-59-

32. The method according to claim 22, wherein in step (d), at least one of normal specimen, presence of heparin, abnormal fibrinogen, oral anticoagulant, and one or more Factor deficiencies are presented on an APTT map.

33. The method according to claim 22, wherein step (d) further comprises:

- (i) selecting weight vectors;
- 10 (ii) selecting sample from training set;
- (iii) identifying best matching winning neuron at a particular time;
- (iv) updating weight vectors; and
- (v) repeating steps i) through iv) until map
- 15 reaches equilibrium.

34. The method according to claim 22, wherein in step (c), data from the time-dependent measurement profiles is transformed into a plurality of predictor variables that characterize timing, rate and magnitude of changes during the time-dependent measurement profile, and wherein said predictor variables are used as input for neural networks.

25 35. The method according to claim 22, wherein in steps (a) and (b), a plurality of one or more coagulation assays are performed to provide said time-dependent measurement profiles.

30 36. The method according to claim 25, wherein a plurality of maps are provided for presenting said data. The method according to claim 36, wherein said plurality of maps comprise normal sample and abnormal sample maps.

-60-

37. The method according to claim 36, wherein a plurality of maps are provided for presentation of data, each map trained with data from one or more coagulation assays.

5

38. The method according to claim 22, wherein said each of a plurality of known blood samples are normal samples.

10

39. The method according to claim 22, wherein the definition of said predictor variables is a position in a self-organizing feature map, trained with data from said at least one time-dependent measurement profiles for said known blood samples.

15

40. The method according to claim 22, wherein the predictor variables are in terms of a standard deviation from a mean of at least one known blood sample population, and wherein said unknown blood sample is characterized by variation from the mean of said known blood samples for each predictor variable.

20

41. A method for estimating the concentration of one or more proteins in the clotting cascade from at least one time-dependent measurement profile, comprising:

25

a) performing at least one time-dependent measurement on an unknown sample and measuring a respective property over time so as to derive a time-dependent measurement profile;

30

b) defining a set of a plurality of predictor variables which sufficiently define the data of the time-dependent measurement profile;

c) deriving a model that represents the relationship between the abnormal level of said one or

35

-61-

more proteins in the clotting cascade and the set of predictor variables; and

- d) utilizing the model of step c) to estimate the concentration of said one or more proteins in the  
5 clotting cascade.




FIG. 1




FIG. 2





FIG. 3



$\eta=0.01, \alpha=0.9$

$\eta=0.5, \alpha=0.1$

FIG. 4


 $\eta=0.9, \alpha=0.1$ 

FIG. 5




FIG. 6




FIG. 7




FIG. 8

Hidden Layer Size	Error		$\varphi_{\text{ODB}}$
	$E_{\text{tr}}$	$E_{\text{DV}}$	
2	0.384	0.376	0.848
4	0.386	0.354	0.835
6	0.341	0.328	0.875
8	0.358	0.327	0.857
10	0.346	0.325	0.856
12	0.347	0.322	0.855

FIG. 9




FIG. 10




FIG. 11

12 / 30




FIG. 12

FIG. 13

Predictor Variables	
Predictor Variable	Description
$pv_{j1} = \left(\frac{dT}{dt}\right)_{min}$	minimum of the first derivative
$pv_{j2} = t \text{ at } \left(\frac{dT}{dt}\right)_{min}$	time index of the minimum of the first derivative
$pv_{j3} = \left(\frac{d^2T}{dt^2}\right)_{min}$	minimum of the second derivative
$pv_{j4} = t \text{ at } \left(\frac{dT^2}{dt^2}\right)_{min}$	index of the minimum of the second derivative
$pv_{j5} = \left(\frac{d^2T}{dt^2}\right)_{max}$	maximum of the second derivative
$pv_{j6} = t \text{ at } \left(\frac{dT^2}{dt^2}\right)_{max}$	index of the maximum of the second derivative
$pv_{j7} = T_{t0} - T_{tR}$	overall change in transmittance during the reaction




FIG. 14

15 / 30




FIG. 15

16 / 30




FIG. 16

17 / 30




FIG. 17

18 / 30




FIG. 18




FIG. 19

20 / 30




FIG. 20

21 / 30




FIG. 21

Condition	Training Set		Cross-Validation Set	
	Negative	Positive	Negative	Positive
FII < 30%	346	32	362	19
FV < 30%	362	12	366	12
FVII < 30%	354	32	343	35
FVIII < 30%	342	32	367	19
FIX < 30%	344	26	360	15
FX < 30%	294	76	324	58
FX < 10%	338	32	369	13
FX < 50%	266	104	289	93
FXI < 30%	358	12	367	12
FXII < 30%	346	32	362	24

FIG. 22

22/30

Results of classification of coagulation factor deficiencies as determined from area under ROC curves. Results are shown for classification based on APTT and PT clot times (APTT CT and PT CT, respectively) and from neural networks using APTT optical data parameter sets (APTT NN), PT data parameters (PT NN) and combined data sets from both assays (APTT-PT NN). Results are expressed as area under ROC curves and the associated standard error (SE) calculated according to [19].

Factor	Condition Cut-off	APTT-PT NN		APTT NN		PT NN		APTT CT		PT CT		Comments
		Area	SE	Area	SE	Area	SE	Area	SE	Area	SE	
FII	30%	0.999	0.001	0.998	0.002	0.876	0.032	0.594	0.044	0.922	0.016	Best results for APTT NN, APTT-PT NN
FV	30%	0.787	0.087	0.942	0.018	0.760	0.090	0.412	0.076	0.815	0.026	Best results for APTT NN
FVII	30%	0.791	0.045	0.724	0.049	0.728	0.041	0.661	0.036	0.882	0.017	NNs do not provide either greater area under curve or higher specificity (Fig. 5)
FVIII	30%	0.826	0.065	0.794	0.060	0.752	0.055	0.789	0.027	0.423	0.082	NNs do not give greater area under curve; do tend toward higher specificity (Fig. 6)
FIX	30%	0.691	0.087	0.634	0.090	0.961	0.011	0.622	0.090	0.738	0.073	Best results for PT NN
FX	30%	0.827	0.041	0.809	0.043	0.830	0.025	0.579	0.034	0.894	0.016	NNs do not give greater area under curve; do tend toward higher specificity (Fig. 11)
FXI	30%	0.790	0.093	0.692	0.080	0.826	0.033	0.509	0.091	0.675	0.077	Best results for APTT-PT NN if greater specificity is desired (Fig. 8)
FXII	30%	0.902	0.039	0.710	0.055	0.586	0.067	0.659	0.070	0.530	0.058	Best results for APTT-PT NN

FIG. 23

23/ 30

Areas under ROC curves for three networks trained to classify factor deficiencies based on three different diagnostics cutoffs (10%, 30%, and 50%). The area under the ROC curve for PT clot time is also included. ROC curves for APTT clot time are not shown due to the generally accepted insensitivity of APTT clot time to FX (as exhibited in Table II). SE is the standard error associated with the area.

Condition		APTT-PT NN		PT CT	
Factor	Cut-off	Area	SE	Area	SE
FX < 10%		0.994	0.004	0.951	0.016
FX < 30%		0.827	0.041	0.894	0.016
FX < 50%		0.748	0.035	0.900	0.016

FIG. 24

Results from linear regressions comparing factor concentrations estimated using neural networks with measured factor concentrations, including the slope, intercept, and the Pearson product moment correlation coefficient ( $r$ ). Pearson correlation coefficients are also included for linear regressions comparing APTT and PT clot times with measured factor concentrations.

Factor	APTT-PT NN			APTT Clot Time	PT Clot Time
	Slope	Intercept	$r$	$r$	$r$
FII	0.53	46.7	0.62	0.05	0.05
FV	0.31	64.2	0.45	0.07	0.01
FVII	0.18	8.5	0.32	0.17	0.08
FVIII	-0.14	140.5	0.02	0.15	0.13
FIX	0.38	60.7	0.54	0.26	0.15
FX	0.50	53.2	0.60	0.11	0.13
FXI	0.20	75.4	0.37	0.27	0.08
FXII	0.35	54.8	0.51	0.10	0.08
Fibrinogen	0.89	61.9	0.97	0.07	0.07

FIG. 25

24 / 30




FIG. 26

25 / 30




FIG. 27

26 / 30




FIG. 28

SUBSTITUTE SHEET (RULE 26)

27 / 30




FIG. 29

SUBSTITUTE SHEET (RULE 26)

28/ 30

Sensitivity, specificity, efficiency, predictive value of positive test (PPV), and predictive power of negative test (NPV) for self-organizing feature maps trained using learning vector quantization to predict factor-deficiencies or heparin therapy based on either APTT or PT parameters.

Deficiency or Condition	APTT					PT				
	Sensitivity	Specificity	PPV	NPV	Efficiency	Sensitivity	Specificity	PPV	NPV	Efficiency
FII < 30%	0.84	0.93	0.39	0.99	0.93	0.79	0.96	0.51	0.99	0.95
FV < 30%	0.00	0.98	0.00	0.97	0.95	0.00	0.99	0.00	0.97	0.96
FVII < 30%	0.22	0.97	0.42	0.92	0.90	0.03	0.97	0.09	0.91	0.88
FVIII < 30%	0.33	0.96	0.21	0.98	0.94	0.00	0.96	0.00	0.97	0.93
FIX < 30%	0.47	0.91	0.18	0.98	0.89	0.00	0.96	0.00	0.96	0.92
FX < 30%	0.62	0.85	0.43	0.93	0.82	0.66	0.86	0.46	0.93	0.83
FXI < 30%	0.67	0.96	0.35	0.99	0.95	1.00	0.96	0.45	1.00	0.96
FXII < 30%	0.79	0.90	0.34	0.98	0.89	0.50	0.92	0.29	0.97	0.89
Heparin < 0.051 U/ml	0.76	0.86	0.72	0.88	0.83	0.77	0.74	0.59	0.87	0.75

FIG. 30

29 / 30




FIG. 31

30 / 30




FIG. 32

# INTERNATIONAL SEARCH REPORT

International application No.  
PCT/US98/27865

<b>A. CLASSIFICATION OF SUBJECT MATTER</b> IPC(6) :GOIN 33/49, 33/86; GO6F 19/00 US CL :436/69; 422/73; 73/64.41, 64.43; 702/22 According to International Patent Classification (IPC) or to both national classification and IPC		
<b>B. FIELDS SEARCHED</b> Minimum documentation searched (classification system followed by classification symbols) U.S. : 436/69; 422/73; 73/64.41, 64.43; 702/19, 22, 25, 27, 28, 30, 32 Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)		
<b>C. DOCUMENTS CONSIDERED TO BE RELEVANT</b>		
Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y, P	5,708,591 A (GIVENS et al.) 13 January 1998, column 4, lines 25-68 and column 5.	1-41
A	5, 646,046 A (FISCHER et al.) 08 July 1997, column 5, lines 1-49.	1-41
A	5,156,974 A (GROSSMAN et al.) 20 October 1992, column 4, lines 12-54.	1-41
<input type="checkbox"/> Further documents are listed in the continuation of Box C. <input type="checkbox"/> See patent family annex.		
*A* document defining the general state of the art which is not considered to be of particular relevance *E* earlier document published on or after the international filing date *L* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified) *O* document referring to an oral disclosure, use, exhibition or other means *P* document published prior to the international filing date but later than the priority date claimed	*T* later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention *X* document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone *Y* document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art *Z* document member of the same patent family	
Date of the actual completion of the international search 10 MAY 1999		Date of mailing of the international search report 20 MAY 1999
Name and mailing address of the ISA/US Commissioner of Patents and Trademarks Box PCT Washington, D.C. 20231 Facsimile No. (703) 305-3230		Authorized officer MAUREEN WALLENHORST Telephone No. (703) 308-0661

**This Page is Inserted by IFW Indexing and Scanning  
Operations and is not part of the Official Record**

## **BEST AVAILABLE IMAGES**

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images include but are not limited to the items checked:

- ☐ **BLACK BORDERS**
- ☐ **IMAGE CUT OFF AT TOP, BOTTOM OR SIDES**
- ☐ **FADED TEXT OR DRAWING**
- ☐ **BLURRED OR ILLEGIBLE TEXT OR DRAWING**
- ☐ **SKEWED/SLANTED IMAGES**
- ☐ **COLOR OR BLACK AND WHITE PHOTOGRAPHS**
- ☐ **GRAY SCALE DOCUMENTS**
- ☐ **LINES OR MARKS ON ORIGINAL DOCUMENT**
- ☐ **REFERENCE(S) OR EXHIBIT(S) SUBMITTED ARE POOR QUALITY**
- ☐ **OTHER:** \_\_\_\_\_

**IMAGES ARE BEST AVAILABLE COPY.**

**As rescanning these documents will not correct the image problems checked, please do not report these problems to the IFW Image Problem Mailbox.**